Cargando…

Female Mucopolysaccharidosis IIIA Mice Exhibit Hyperactivity and a Reduced Sense of Danger in the Open Field Test

Reliable behavioural tests in animal models of neurodegenerative diseases allow us to study the natural history of disease and evaluate the efficacy of novel therapies. Mucopolysaccharidosis IIIA (MPS IIIA or Sanfilippo A), is a severe, neurodegenerative lysosomal storage disorder caused by a defici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langford-Smith, Alex, Langford-Smith, Kia J., Jones, Simon A., Wynn, Robert F., Wraith, J. E., Wilkinson, Fiona L., Bigger, Brian W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196509/ https://www.ncbi.nlm.nih.gov/pubmed/22028789 http://dx.doi.org/10.1371/journal.pone.0025717

Ejemplares similares

Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
por: Wilkinson, Fiona L., et al.
Publicado: (2012)

Heparan Sulfate Inhibits Hematopoietic Stem and Progenitor Cell Migration and Engraftment in Mucopolysaccharidosis I
por: Watson, H. Angharad, et al.
Publicado: (2014)

Assessment of Sleep in Children with Mucopolysaccharidosis Type III
por: Mahon, Louise Victoria, et al.
Publicado: (2014)

Signal One and Two Blockade Are Both Critical for Non-Myeloablative Murine HSCT across a Major Histocompatibility Complex Barrier
por: Langford-Smith, Kia J., et al.
Publicado: (2013)

Genistein Improves Neuropathology and Corrects Behaviour in a Mouse Model of Neurodegenerative Metabolic Disease
por: Malinowska, Marcelina, et al.
Publicado: (2010)

From hypertransaminasemia to mucopolysaccharidosis IIIA
por: Krawiec, Paulina, et al.
Publicado: (2014)

Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal Disease
por: Sergijenko, Ana, et al.
Publicado: (2013)

Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA
por: Parker, Helen, et al.
Publicado: (2020)

Prediction of phenotypic severity in mucopolysaccharidosis type IIIA
por: Knottnerus, Suzan J. G., et al.
Publicado: (2017)

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases
por: Langford-Smith, Kia Jane, et al.
Publicado: (2010)

Bioinformatics classification of mutations in patients with Mucopolysaccharidosis IIIA
por: Tanwar, Himani, et al.
Publicado: (2019)

Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex Vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA
por: Ellison, Stuart M., et al.
Publicado: (2019)

Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA
por: Anson, Donald S, et al.
Publicado: (2007)

Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA
por: Sorrentino, Nicolina Cristina, et al.
Publicado: (2019)

Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
por: Bugiani, Marianna, et al.
Publicado: (2023)

Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA
por: Sidhu, Navdeep S., et al.
Publicado: (2014)

Distribution of Heparan Sulfate Oligosaccharides in Murine Mucopolysaccharidosis Type IIIA
por: Mason, Kerryn, et al.
Publicado: (2014)

Neurocognitive testing in a murine model of mucopolysaccharidosis type IIIA
por: Pericleous, Kleopatra, et al.
Publicado: (2023)

An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome)
por: Pollock, Kari, et al.
Publicado: (2023)

An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III
por: Cross, Elaine M, et al.
Publicado: (2014)

Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy
por: Chen, Yonghong, et al.
Publicado: (2018)

Cardiac disease as the presenting feature of mucopolysaccharidosis type IIIA: A case report
por: Ribeiro, Erlane Marques, et al.
Publicado: (2014)

A novel mutation of SGSH and clinical features analysis of mucopolysaccharidosis type IIIA
por: Li, Xiaohua, et al.
Publicado: (2018)

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
por: Horgan, Claire, et al.
Publicado: (2022)

Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse
por: Paget, Tamara L., et al.
Publicado: (2021)

Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction
por: Magat, Jenna, et al.
Publicado: (2022)

A Multiparametric Computational Algorithm for Comprehensive Assessment of Genetic Mutations in Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome)
por: Ugrinov, Krastyu G., et al.
Publicado: (2015)

Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector
por: Bobo, Tierra A., et al.
Publicado: (2020)

The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK
por: Moore, David, et al.
Publicado: (2008)

Airway-Related Symptoms and Surgeries in Patients With Mucopolysaccharidosis I
por: Arn, Pamela, et al.
Publicado: (2015)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice
por: Gustavsson, Susanne, et al.
Publicado: (2019)

Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group
por: Köhn, Anja F., et al.
Publicado: (2020)

Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II
por: Gleitz, Hélène F. E., et al.
Publicado: (2017)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)

Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome
por: Pal, Abhijit Ricky, et al.
Publicado: (2015)

Endothelial Progenitor Cells: New Targets for Therapeutics for Inflammatory Conditions With High Cardiovascular Risk
por: Edwards, Nicola, et al.
Publicado: (2018)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hpkpeie3ttjlpm427e53q4e902